Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Una discusión entre  el Dr. Luis Gerardo García Demuner y el Dr. Samuel Navarro: antenimiento de la atención del VIH durante la pandemia de COVID-19 en México

Vea esta discusión de profesores expertos sobre la colisión de VIH y COVID-19 en México, incluyendo, el impact del VIH en la prevalencia y la gravedad de la enfermedad de COVID-19, el impacto de la COVID-19 en la atención al VIH en México, y las estrategias e intervenciones para mitigar el impacto de la COVID-19 en la atención del VIH.
person default
Luis G. García Demuner, MD
Samuel Navarro, MD
Luis E. Soto-Ramirez, MD
Released: December 22, 2020

Information on this Educational Activity

Faculty

Luis E. Soto-Ramirez, MD

Head, Molecular Virology Lab
Department of Infectious Diseases
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
Head, Infectious Diseases and Epidemiology
Hospital Médica Sur
Mexico City, Mexico

El Dr. Luis Enrique Soto-Ramírez ha informado que cobró honorarios por asesoramiento de Gilead Sciences, GlaxoSmithKline, Merck y ViiV Healthcare, y honorarios por servicios no relacionados con CME/CE de Gilead Sciences, Janssen y Merck.
Luis G. García Demuner, MD

Médico adscrito
Servicio de Infectología
Hospital General “Dr. Fernando Quiroz Gutiérrez”, ISSSTE
CoordinadorMédico del turnoVespertino, 
ClínicaEspecializadaCondesa, SSsaludCdMx
Ciudad de México

El Dr. Luis Gerardo García Demuner ha informado que cobró honorarios por asesoramiento de GlaxoSmithKline, y honorarios por servicios no relacionados con CME/CE de Gilead Sciences y Janssen.
Samuel Navarro, MD

Infectious Diseases Teacher
School of Medicine
Universidad Autonoma de Baja California
Head, Epidemiology and HIV Clinic
Tijuana, Mexico

El Dr. Samuel Navarro ha informado que cobró honorarios por asesoramiento de Gilead Sciences, Merck y Sandoz, y honorarios por servicios no relacionados con CME/CE de Gilead Sciences, Janssen, Merck, Pfizer y Sandoz, así como fondos en forma de subvención para sus investigaciones de AbbVie, Janssen, Merck, Pfizer y Roche.

Staff

Jennifer Blanchette, PhD

Senior Scientific Director

Jennifer M. Blanchette, PhD, no tiene conflictos de intereses relevantes que reportar
Edward King, MA

Executive Vice President

Edward King, MA, no tiene conflictos de intereses relevantes que reportar.
Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, no tiene conflictos de intereses relevantes que reportar.
Tiffany Hensley-McBain, PhD

Scientific Director

Tiffany Hensley-McBain, PhD, no tiene conflictos de intereses relevantes que reportar.

Program Medium

This program has been made available online.

Related Content

Short video log from Rajesh Gandhi, MD, on the efficacy and safety of COVID-19 vaccines in older persons and persons with HIV

Rajesh T. Gandhi, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: January 21, 2021 Expired: January 20, 2022

Free expert-authored slides reviewing a patient case and the data on efficacy and safety of authorized COVID-19 vaccines in older persons with HIV

Rajesh T. Gandhi, MD Released: January 21, 2021

Short video log from Rajesh Gandhi, MD, on COVID-19 risk in older persons with HIV and implications for COVID-19 vaccine recommendation

Rajesh T. Gandhi, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: January 20, 2021 Expired: January 19, 2022

Free expert-authored slides reviewing a patient case and the data on COVID-19 risk in persons with HIV that may inform vaccine prioritization

Rajesh T. Gandhi, MD Released: January 20, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue